213 related articles for article (PubMed ID: 38665943)
21. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
22. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
23. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang Y; Sokol L
Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
[TBL] [Abstract][Full Text] [Related]
24. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
25. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
26. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
27. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
28. Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ; Wilson NR; Pemmaraju N
Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
30. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Case.
Al-Alwan A; Khalid F; Vyas C; Sirpal V; Bader H
J Community Hosp Intern Med Perspect; 2023; 13(4):79-81. PubMed ID: 37868236
[TBL] [Abstract][Full Text] [Related]
31. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
Abla D; Abboud MR; Noun D; Tarek N; Pemmaraju N
Leuk Res Rep; 2022; 17():100313. PubMed ID: 35462725
[TBL] [Abstract][Full Text] [Related]
32. Tagraxofusp in myeloid malignancies.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
[TBL] [Abstract][Full Text] [Related]
33. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Hammond D; Pemmaraju N
Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy.
Azad F; Zhang J; Miranda CJ; Gravina M
Cureus; 2022 Dec; 14(12):e33109. PubMed ID: 36726910
[TBL] [Abstract][Full Text] [Related]
35. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
36. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kharfan-Dabaja MA; Cherry M
Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
[TBL] [Abstract][Full Text] [Related]
38. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies.
Kharfan-Dabaja MA; Pemmaraju N; Mohty M
Clin Hematol Int; 2019 Mar; 1(1):2-9. PubMed ID: 34595405
[TBL] [Abstract][Full Text] [Related]
40. [Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].
Nguyen K; Korsing S; Mansour Y; Meier K
Dermatologie (Heidelb); 2023 Oct; 74(10):787-792. PubMed ID: 37407876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]